In the research collaboration, Skyline will use its technologies in the area of genetic profiling and bioinformatics and work with Janssen to generate and analyze diagnostic information related to the use of an investigational compound.

Skyline will receive R&D funding and payments on the achievement of certain research milestones.

Skyline Diagnostics CEO Henk Vietor said this collaboration provides both companies the opportunity to develop a personalized medicine approach to help identify patients at increased risk of side effects.

The company has translated several important scientific discoveries into diagnostics.

The products, called Profilers, are based on gene expression and provide the clinician in-depth insight in the prognosis of individual patients and facilitate the treatment decision making process.